What’s at stake: Kimer Med’s Series A funding round is crucial for advancing its groundbreaking work in developing broad-spectrum antiviral drugs, targeting an array of untreated viral diseases.
Background: Since its inception in 2020, Kimer has developed innovative platform for rapid antiviral drug development and a focus on combating diseases such as dengue fever.
Key players: Rick Kiessig, Phil Oliver, Callaghan Innovation, Massachusetts Institute of Technology, The University of Auckland.
Nelson-based biotech startup Kimer Med is running a Series A funding round, seeking to raise $14 million by August. The company has been developing a platform to develop broard-spectrum antiviral drugs, which could be a game-changer in the fight against viral diseases.
The Series A round follows a
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
What’s at stake: Kimer Med’s Series A funding round is crucial for advancing its groundbreaking work in developing broad-spectrum antiviral drugs, targeting an array of untreated viral diseases.
Background: Since its inception in 2020, Kimer has developed innovative platform for rapid antiviral drug development and a focus on combating diseases such as dengue fever.
Key players: Rick Kiessig, Phil Oliver, Callaghan Innovation, Massachusetts Institute of Technology, The University of Auckland.
